Farmakoterapie po infarktu myokardu
| Title in English | Pharmacotherapy after myocardial infarction |
|---|---|
| Authors | |
| Year of publication | 2011 |
| Type | Article in Periodical |
| Magazine / Source | Interní medicína pro praxi |
| MU Faculty or unit | |
| Citation | |
| Field | Cardiovascular diseases incl. cardiosurgery |
| Keywords | myocardial infarction; pharmacotherapy; doses; target levels |
| Description | Early reperfusion is currently the mainstay of treatment for acute coronary syndrome. Thanks to a network of 22 catheterization centres, the Czech Republic is among countries with a high availability of reperfusion therapy. Approximately 28,000 patients are thus treated annually. Successful reperfusion must be followed by lifestyle measures including not smoking, maintaining a healthy weight, etc. All this must be complemented with effective pharmacotherapy whose goal is to prevent left ventricular remodelling, coronary artery restenosis, rethrombosis and arrhythmias. Four drug groups are designed for this purpose: renin-angiotensin-aldosterone system blockers, beta blockers, antiplatelet agents and statins. The FARIM (FARmakoterapie po Infarktu Myokardu – Pharmacotherapy after Myocardial Infarction) survey conducted in the practices of physicians in the Czech Republic found a very good rate of prescribing the recommended drugs with each of the drug groups mentioned above being prescribed in about 90% of patients after myocardial infarction. Achieving the target levels of blood pressure and cholesterol was also found to be of a good standard while the doses of some agents were inadequate. |
| Related projects: |